Education · Tier 4
· Last Reviewed May 12, 2026· PSI Editorial Board· IndependentWhat Bloodwork Is Required for GLP-1 Therapy?
The honest reference for GLP-1 receptor agonist baseline bloodwork across semaglutide, tirzepatide, and liraglutide therapy, anchored in FDA labels and ADA 2024 Standards of Care.
GLP-1 receptor agonist therapy requires baseline hemoglobin A1c, eGFR via creatinine, lipase, and lipid panel.
The FDA labels for Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, and Victoza specify this framework.
The ADA 2024 Standards of Care anchor type 2 diabetes monitoring.
SELECT 2023 supports cardiovascular outcomes tracking.
Quick Answer
GLP-1 receptor agonist therapy with semaglutide, tirzepatide, and liraglutide requires four foundational baseline markers. The markers cover glycemic control, kidney function, pancreatic baseline, and cardiovascular risk.
For Semaglutide (Wegovy NDA 215256, Ozempic NDA 209637), baseline includes hemoglobin A1c, eGFR via creatinine, lipase, and lipid panel. The FDA labels and ADA 2024 Standards of Care anchor the framework.
For Tirzepatide (Zepbound NDA 217806, Mounjaro NDA 215866), baseline includes the same four foundational markers. SURMOUNT-1 2022 demonstrated approximately 21 percent weight reduction with tirzepatide.
For Liraglutide (Saxenda, Victoza), baseline includes the same four foundational markers. The framework applies across the GLP-1 receptor agonist class.
Additional context-specific markers include TSH for the medullary thyroid carcinoma boxed warning in some FDA labels. Pregnancy testing applies for patients of reproductive age. Gastrointestinal symptom history supports baseline tolerability assessment.
Cardiovascular outcomes monitoring is anchored in SELECT 2023 (Lincoff et al. NEJM) and SUSTAIN-6 (Marso et al. NEJM 2016). SELECT demonstrated approximately 20 percent MACE reduction with semaglutide in obesity without diabetes.
Monitoring follows a four-stage cadence. The stages are baseline at week 0, early follow-up at week 4 to 8, and stabilization at month 3. The maintenance stage is at month 6 with annual continuation. See Bloodwork Before Peptide Therapy for the full framework. Also see Compounded vs FDA-Approved for prescription pathway context.
The four foundational baseline markers cover glycemic control, kidney function, pancreatic baseline, and cardiovascular risk. Hemoglobin A1c establishes glycemic control or screens for unrecognized diabetes. The eGFR via creatinine supports kidney function assessment and dose adjustment. Lipase provides pancreatic baseline given the FDA acute pancreatitis warning. The lipid panel supports cardiovascular risk stratification anchored in SELECT 2023 and SUSTAIN-6. Additional context-specific markers include TSH for the medullary thyroid carcinoma boxed warning. Pregnancy testing applies to patients of reproductive age.
GLP-1 BLOODWORK FRAMEWORK
At a Glance: Bloodwork for GLP-1 Therapy
| Marker / Stage | Subtitle | Animal Evidence | Human Evidence | Clinical Rationale |
|---|---|---|---|---|
| Hemoglobin A1c baseline | Glycemic control baseline or unrecognized diabetes screening | — | Strong | Required across all GLP-1 RA drugs for type 2 diabetes baseline or chronic weight management screening per ADA 2024 |
| eGFR via creatinine baseline | Kidney function baseline for dose adjustment | — | Strong | FDA labels specify kidney function assessment before initiation for Ozempic, Wegovy, Mounjaro, and Zepbound |
| Lipase baseline | Pancreatic baseline given acute pancreatitis warning | — | Strong | FDA prescribing information includes acute pancreatitis warning. Baseline lipase establishes pre-existing elevation status |
| Lipid panel baseline | Cardiovascular risk stratification baseline | — | Strong | Supports SELECT 2023 cardiovascular benefit framework and SUSTAIN-6 type 2 diabetes cardiovascular monitoring |
| TSH baseline (class-specific addition) | Thyroid baseline for medullary thyroid carcinoma boxed warning context | — | Strong | Some GLP-1 FDA labels include medullary thyroid carcinoma boxed warning. Baseline TSH supports contraindication screening |
| Pregnancy testing (reproductive age context) | Pregnancy exclusion for patients of reproductive age | — | Strong | GLP-1 receptor agonist therapy is contraindicated in pregnancy per FDA labels. Baseline testing applies |
| Class-specific markers (gastrointestinal context) | Gastrointestinal tolerability and gastroparesis-related context | — | Moderate | FDA labels include gastroparesis-related warnings. Baseline GI symptom history strengthens framework |
| Four-stage monitoring cadence | Baseline, early follow-up, stabilization, maintenance | — | Strong | Baseline week 0, early follow-up week 4-8, stabilization month 3, maintenance month 6 plus annual continuation |
Six Things You Need to Know About GLP-1 Bloodwork
This page covers GLP-1 receptor agonist baseline bloodwork in detail. The framework spans the FDA-approved peptide class including semaglutide, tirzepatide, and liraglutide. Section one covers the four foundational baseline markers. Section two covers cardiovascular outcomes monitoring. Section three addresses class-specific context markers. Section four covers the four-stage monitoring cadence.
Hemoglobin A1c Establishes Glycemic Control or Screens for Unrecognized Diabetes
Hemoglobin A1c is the foundational baseline marker for GLP-1 receptor agonist therapy. For type 2 diabetes indications, A1c establishes baseline glycemic control. For chronic weight management indications without diabetes, A1c screens for unrecognized type 2 diabetes or pre-diabetes.
Per ADA 2024 Standards of Care, hemoglobin A1c diagnostic thresholds are A1c above 6.5 percent for type 2 diabetes diagnosis and A1c 5.7 percent to 6.4 percent for pre-diabetes. For chronic weight management indications with Wegovy or Saxenda (FDA labels for weight management), baseline A1c screens for unrecognized type 2 diabetes. For type 2 diabetes indications with Ozempic, Victoza, Mounjaro, or Trulicity, baseline A1c establishes glycemic control before therapy initiation. The FDA prescribing information for each GLP-1 receptor agonist specifies A1c monitoring across the therapy course. Monitoring intervals follow ADA 2024 guidance: at least twice per year for patients meeting glycemic targets and quarterly for patients not meeting targets or with recent therapy changes. The PSI four-stage cadence captures the monitoring framework per FDA prescribing information.
eGFR via Creatinine Supports Kidney Function and Dose Adjustment
Estimated glomerular filtration rate (eGFR) via serum creatinine is required at baseline for GLP-1 receptor agonist therapy per FDA prescribing information. Dose adjustment depends on kidney function across the class.
The FDA prescribing information for Ozempic specifies kidney function assessment before initiation. The FDA prescribing information for Wegovy specifies the same framework. The FDA prescribing information for Mounjaro and Zepbound specifies kidney function monitoring. Baseline eGFR establishes the framework for ongoing monitoring across the therapy course. For patients with chronic kidney disease, GLP-1 receptor agonist dose adjustment may apply per FDA labels. For patients on dialysis or end-stage renal disease, the FDA labels include specific contraindications and dose modifications. Monitoring intervals follow FDA prescribing information with typical re-check at month 3 stabilization stage and annual continuation thereafter. Specialty coordination with nephrology applies for patients with established kidney disease.
Lipase Provides Pancreatic Baseline for the FDA Acute Pancreatitis Warning
Lipase is required at baseline given the FDA acute pancreatitis warning in GLP-1 receptor agonist prescribing information. Baseline lipase establishes whether elevation is pre-existing before therapy initiation.
The FDA prescribing information for all GLP-1 receptor agonists (Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza) includes an acute pancreatitis warning. The warning describes post-marketing reports of acute pancreatitis including hemorrhagic and necrotizing pancreatitis in patients on GLP-1 receptor agonist therapy. The baseline lipase establishes the patient's pre-existing pancreatic marker status. For patients with elevated baseline lipase, additional evaluation for pancreatic disease is required before therapy initiation. For patients with normal baseline lipase, the FDA framework specifies symptom-driven re-check (persistent severe abdominal pain, vomiting). For symptomatic elevation during therapy, FDA prescribing information specifies discontinuation pending pancreatic evaluation. Adverse event reporting through FDA MedWatch applies for serious pancreatic adverse events.
Lipid Panel Supports Cardiovascular Risk Stratification per SELECT and SUSTAIN-6
Lipid panel baseline supports cardiovascular risk stratification. The framework anchors in SELECT 2023 (Lincoff et al. NEJM) demonstrating approximately 20 percent MACE reduction with semaglutide in obesity without diabetes and SUSTAIN-6 (Marso et al. NEJM 2016) demonstrating cardiovascular benefit in type 2 diabetes.
SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a 17,604-patient cardiovascular outcomes trial published 2023 in NEJM. The trial demonstrated approximately 20 percent reduction in major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) with semaglutide 2.4 mg weekly versus placebo over a median 39.8 months follow-up in patients with overweight or obesity and established cardiovascular disease without diabetes. SUSTAIN-6 was a 3,297-patient cardiovascular outcomes trial published 2016 in NEJM. The trial demonstrated cardiovascular benefit of semaglutide in patients with type 2 diabetes and high cardiovascular risk. Baseline lipid panel establishes the cardiovascular risk profile before GLP-1 receptor agonist therapy. Monitoring intervals follow ADA 2024 Standards of Care with lipid re-check at month 6 stabilization stage and annual continuation thereafter.
Class-Specific Markers Include TSH, Pregnancy Testing, and Gastrointestinal Context
Additional class-specific baseline markers include thyroid-stimulating hormone (TSH) for the medullary thyroid carcinoma boxed warning context, pregnancy testing for patients of reproductive age, and gastrointestinal symptom history for the FDA gastroparesis-related warnings.
Some GLP-1 receptor agonist FDA labels include a medullary thyroid carcinoma boxed warning based on rodent thyroid C-cell tumor findings. The boxed warning specifies contraindication in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Baseline TSH supports contraindication screening and provides a marker for ongoing monitoring. GLP-1 receptor agonist therapy is contraindicated in pregnancy per FDA labels. Baseline pregnancy testing applies for patients of reproductive age. Counseling on contraception during therapy is standard per FDA prescribing information. The FDA labels also include gastroparesis-related warnings. Baseline gastrointestinal symptom history establishes pre-existing GI motility status. For patients with established gastroparesis, alternative therapy consideration applies per specialty coordination. Specialty coordination with endocrinology supports complex evaluation when type 2 diabetes is concurrent.
Four-Stage Monitoring Cadence Anchors Continuous Quality Care
Monitoring across GLP-1 receptor agonist therapy follows a four-stage cadence: baseline at week 0, early follow-up at week 4 to 8, stabilization at month 3, and maintenance at month 6 with annual continuation thereafter.
Stage 1 baseline at week 0 establishes the full panel: A1c, eGFR via creatinine, lipase, lipid panel, TSH, and pregnancy testing as applicable. Stage 2 early follow-up at week 4 to 8 tracks gastrointestinal tolerability, A1c trajectory, side effect emergence, and dose titration decisions per FDA prescribing information. Stage 3 stabilization at month 3 captures steady-state therapy response: weight loss trajectory for chronic weight management, A1c response for type 2 diabetes, lipid panel re-check, and kidney function re-check. Stage 4 maintenance at month 6 confirms long-term efficacy and safety. Annual continuation thereafter applies the full baseline panel re-check. Adverse event reporting through FDA MedWatch applies for serious events. The cadence anchors continuity of care across primary care, endocrinology, weight medicine, and other relevant specialty contexts.
Lab Panels by Context
GLP-1 RA Foundational Baseline Panel
GLP-1 receptor agonist · applies to: semaglutide (Wegovy / Ozempic), tirzepatide (Zepbound / Mounjaro), liraglutide (Saxenda / Victoza)
The four foundational baseline markers apply uniformly across the GLP-1 receptor agonist class per FDA prescribing information. The framework anchors in ADA 2024 Standards of Care for type 2 diabetes contexts plus SELECT 2023 and SUSTAIN-6 cardiovascular outcomes.
Context: FDA-approved weight management and type 2 diabetes peptide therapy. Routes through retail pharmacy with insurance prior authorization. Class-uniform baseline framework.
| Test | Why ordered | Monitoring |
|---|---|---|
| Hemoglobin A1c | Glycemic control baseline for type 2 diabetes indications or unrecognized diabetes screening for chronic weight management indications per ADA 2024 Standards of Care diagnostic thresholds. | baseline, month 3, month 6, annual or quarterly for non-targets |
| eGFR via creatinine | Kidney function assessment for dose adjustment per FDA prescribing information across the GLP-1 RA class. Establishes baseline for ongoing monitoring of kidney function across therapy course. | baseline, month 3, annual |
| Lipase | Pancreatic baseline given FDA acute pancreatitis warning common across GLP-1 RA labels. Establishes pre-existing elevation status before therapy initiation. | baseline, as-needed if symptoms develop |
| Lipid panel | Cardiovascular risk stratification baseline supporting SELECT 2023 demonstrated ~20 percent MACE reduction in obesity and SUSTAIN-6 cardiovascular benefit in type 2 diabetes plus LEADER liraglutide benefit. | baseline, month 6, annual |
GLP-1 RA Class-Specific Context Markers
GLP-1 receptor agonist (class-specific additions) · applies to: all GLP-1 RA drugs with FDA boxed warnings, patients of reproductive age, patients with gastroparesis or GI motility history
Class-specific baseline additions apply contextually per FDA labels and patient factors. TSH, pregnancy testing, and gastrointestinal symptom history strengthen the framework based on FDA boxed warnings and patient context.
Context: Additional baseline markers triggered by FDA boxed warnings and patient-specific factors. Not all GLP-1 labels carry every boxed warning so application is drug-specific.
| Test | Why ordered | Monitoring |
|---|---|---|
| Thyroid-stimulating hormone (TSH) | Medullary thyroid carcinoma boxed warning context. Some GLP-1 FDA labels include MTC boxed warning based on rodent thyroid C-cell tumor findings. Baseline TSH supports contraindication screening. | baseline, annual |
| Pregnancy testing | GLP-1 receptor agonist therapy is contraindicated in pregnancy per FDA labels. Baseline pregnancy testing applies for patients of reproductive age plus contraception counseling during therapy. | baseline, before dose escalation, as-needed |
| Cardiovascular history and BP baseline | Cardiovascular risk stratification supporting SELECT 2023 framework for obesity without diabetes plus SUSTAIN-6 and LEADER for type 2 diabetes. Baseline BP and history establish framework. | baseline, every visit during titration, annual |
GLP-1 RA Cardiovascular Outcomes Monitoring
GLP-1 receptor agonist (cardiovascular monitoring) · applies to: all GLP-1 RA drugs with cardiovascular outcomes evidence, patients with established cardiovascular disease, patients with elevated cardiovascular risk
Cardiovascular outcomes monitoring across GLP-1 receptor agonist therapy anchors in SELECT 2023 (semaglutide MACE reduction in obesity), SUSTAIN-6 (semaglutide T2D cardiovascular benefit), LEADER (liraglutide T2D cardiovascular benefit), and SURMOUNT-1 (tirzepatide weight reduction).
Context: Cardiovascular evidence base supports baseline cardiovascular risk stratification. For patients with established atherosclerotic cardiovascular disease, the framework directly applies SELECT and SUSTAIN-6 cardiovascular benefit indications.
| Test | Why ordered | Monitoring |
|---|---|---|
| Lipid panel (cardiovascular subset) | Cardiovascular risk stratification baseline. SELECT 2023 demonstrated ~20 percent MACE reduction with semaglutide in obesity plus established cardiovascular disease. | baseline, month 6, annual |
| Blood pressure assessment | Cardiovascular risk stratification including hypertension management. GLP-1 RA therapy can modestly reduce blood pressure. Baseline BP plus titration BP monitoring applies. | baseline, every visit during titration, monthly during maintenance |
| Cardiovascular history review | History of myocardial infarction, stroke, peripheral arterial disease, or heart failure shapes the cardiovascular benefit framework application. | baseline, annual review |
Semaglutide bloodwork: Wegovy 2.4 mg and Ozempic across indications
Baseline framework for Wegovy chronic weight management and Ozempic type 2 diabetes per FDA labels
Semaglutide is the active ingredient in Wegovy (NDA 215256 for chronic weight management at 2.4 mg weekly dose) and Ozempic (NDA 209637 for type 2 diabetes at 0.25 mg to 2.0 mg weekly dose). The same compound under two FDA approvals with different indications and dose ranges. Baseline bloodwork covers the same four foundational markers: hemoglobin A1c, eGFR via creatinine, lipase, and lipid panel.
For Wegovy chronic weight management, the FDA label adds baseline gallbladder disease screening given acute gallbladder disease warning. Baseline pregnancy testing applies for reproductive age patients. The medullary thyroid carcinoma boxed warning applies with baseline TSH supporting contraindication screening. Wegovy is FDA-approved for adults with BMI 30 or above, or BMI 27 with at least one weight-related comorbidity per the FDA label.
For Ozempic type 2 diabetes, the FDA label anchors monitoring in ADA 2024 Standards of Care. Baseline A1c establishes glycemic control. Monitoring intervals follow ADA 2024 guidance at minimum twice per year for patients meeting glycemic targets. SELECT 2023 (Lincoff et al. NEJM) demonstrated cardiovascular benefit of semaglutide in obesity without diabetes. SUSTAIN-6 (Marso et al. NEJM 2016) demonstrated cardiovascular benefit in type 2 diabetes.
Tirzepatide bloodwork: Zepbound chronic weight management and Mounjaro type 2 diabetes
Baseline framework for tirzepatide dual GIP and GLP-1 receptor agonist per FDA labels
Tirzepatide is a dual GIP and GLP-1 receptor agonist. Tirzepatide is the active ingredient in Zepbound (NDA 217806 for chronic weight management at 5 mg to 15 mg weekly dose) and Mounjaro (NDA 215866 for type 2 diabetes at 2.5 mg to 15 mg weekly dose). Baseline bloodwork covers the same four foundational markers as semaglutide: hemoglobin A1c, eGFR via creatinine, lipase, and lipid panel.
SURMOUNT-1 2022 (Jastreboff et al. NEJM) was the pivotal chronic weight management trial. The 2,539-patient trial demonstrated approximately 21 percent weight reduction with tirzepatide 15 mg weekly versus 3 percent with placebo over 72 weeks. The trial anchored Zepbound FDA approval. Baseline lipid panel supports cardiovascular risk stratification framework.
For Mounjaro type 2 diabetes, the FDA label anchors monitoring in ADA 2024 Standards of Care. Baseline A1c establishes glycemic control. Tirzepatide demonstrated superior A1c reduction versus semaglutide in head-to-head SURPASS-2 trial (Frias et al. NEJM 2021). The medullary thyroid carcinoma boxed warning applies. Baseline TSH supports contraindication screening per the boxed warning framework. Pregnancy testing applies for reproductive age patients per FDA label contraindication.
Liraglutide bloodwork: Saxenda chronic weight management and Victoza type 2 diabetes
Baseline framework for liraglutide daily-injection GLP-1 receptor agonist per FDA labels
Liraglutide is a daily-injection GLP-1 receptor agonist. Liraglutide is the active ingredient in Saxenda (FDA-approved for chronic weight management at 3.0 mg daily dose) and Victoza (FDA-approved for type 2 diabetes at 0.6 mg to 1.8 mg daily dose). Baseline bloodwork covers the same four foundational markers: hemoglobin A1c, eGFR via creatinine, lipase, and lipid panel.
LEADER trial (Marso et al. NEJM 2016) was the pivotal cardiovascular outcomes trial for liraglutide. The 9,340-patient trial demonstrated cardiovascular benefit of liraglutide in type 2 diabetes patients with high cardiovascular risk over 3.8 years median follow-up. Baseline lipid panel and cardiovascular risk stratification anchor the framework.
For Saxenda chronic weight management, the FDA label specifies baseline gallbladder disease screening, baseline pregnancy testing for reproductive age patients, and baseline TSH given the medullary thyroid carcinoma boxed warning. For Victoza type 2 diabetes, ADA 2024 Standards of Care anchor the monitoring framework. The daily-injection cadence (versus weekly for semaglutide and tirzepatide) shapes patient preference and adherence considerations. Specialty coordination with endocrinology applies for type 2 diabetes contexts.
Cardiovascular outcomes monitoring across GLP-1 receptor agonist class
SELECT 2023, SUSTAIN-6, LEADER, and the cardiovascular benefit framework
Cardiovascular outcomes monitoring is a central pillar of the GLP-1 receptor agonist evidence base. SELECT 2023 (Lincoff et al. NEJM) was a 17,604-patient cardiovascular outcomes trial demonstrating approximately 20 percent MACE reduction with semaglutide 2.4 mg weekly versus placebo over median 39.8 months in obesity without diabetes plus established cardiovascular disease. SELECT represents the largest cardiovascular outcomes trial in obesity therapy.
SUSTAIN-6 (Marso et al. NEJM 2016) was a 3,297-patient cardiovascular outcomes trial demonstrating cardiovascular benefit of semaglutide in type 2 diabetes patients with high cardiovascular risk. LEADER (Marso et al. NEJM 2016) was the parallel 9,340-patient trial for liraglutide. SURMOUNT-1 (Jastreboff et al. NEJM 2022) was the 2,539-patient weight management trial demonstrating approximately 21 percent weight reduction with tirzepatide.
Baseline cardiovascular risk stratification through lipid panel, blood pressure assessment, and cardiovascular history anchors the monitoring framework. For patients with established atherosclerotic cardiovascular disease, the framework supports the SELECT and SUSTAIN-6 cardiovascular benefit indications. Monitoring intervals follow ADA 2024 Standards of Care with lipid re-check at month 6 stabilization and annual continuation. Specialty coordination with cardiology applies for complex cardiovascular contexts including recent acute coronary syndrome or symptomatic heart failure.
Research Suggests
Direction
GLP-1 receptor agonist baseline bloodwork follows FDA prescribing information for the specific drug and indication. The framework anchors in ADA 2024 Standards of Care and cardiovascular outcomes trials.
The four foundational markers are hemoglobin A1c, eGFR via creatinine, lipase, and lipid panel. The framework applies across semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), and liraglutide (Saxenda, Victoza). Additional class-specific markers include TSH for the medullary thyroid carcinoma boxed warning context, pregnancy testing for patients of reproductive age, and gastrointestinal symptom history for FDA gastroparesis-related warnings. Cardiovascular outcomes monitoring anchors in SELECT 2023, SUSTAIN-6, LEADER, and SURMOUNT-1.
Strongest evidence
The four foundational baseline markers have the strongest evidence anchoring across the GLP-1 receptor agonist class.
Hemoglobin A1c is anchored in ADA 2024 Standards of Care for type 2 diabetes diagnosis and monitoring. The A1c diagnostic thresholds (above 6.5 percent for diabetes, 5.7 to 6.4 percent for pre-diabetes) are standardized. eGFR via creatinine is anchored in FDA prescribing information for kidney function assessment and dose adjustment across the class. Lipase is anchored in the FDA acute pancreatitis warning common across GLP-1 receptor agonist labels. Lipid panel is anchored in cardiovascular outcomes trial frameworks including SELECT 2023 demonstrating approximately 20 percent MACE reduction with semaglutide in obesity without diabetes, SUSTAIN-6 demonstrating cardiovascular benefit in type 2 diabetes, and LEADER demonstrating liraglutide cardiovascular benefit.
Limitations
Class-specific markers including TSH and pregnancy testing apply contextually based on FDA boxed warnings and patient factors.
TSH baseline applies for medullary thyroid carcinoma boxed warning screening. Not all GLP-1 receptor agonist labels carry the same boxed warning, so TSH application is FDA-label-specific. Pregnancy testing applies only for patients of reproductive age. Gastrointestinal symptom history is not a laboratory test but supports clinical context for the gastroparesis-related warnings. For compounded GLP-1 receptor agonist preparations (FDA scrutiny on compounded semaglutide and tirzepatide), AMA Code of Medical Ethics 1.1.5 framework applies plus documented physician verification of pharmacy quality assurance. Discuss compounded GLP-1 pathway with specialty practice for individualized clinical context.
Assessment
The four foundational markers plus class-specific additions establish the GLP-1 receptor agonist baseline framework. The framework anchors continuity of care.
PSI's reading: GLP-1 receptor agonist baseline bloodwork is well-standardized across the FDA-approved class. The four foundational markers (A1c, eGFR, lipase, lipid panel) apply uniformly. Class-specific additions (TSH, pregnancy testing, GI history) apply contextually per FDA labels and patient factors. The cardiovascular outcomes evidence base (SELECT 2023, SUSTAIN-6, LEADER, SURMOUNT-1) anchors lipid panel baseline. The ADA 2024 Standards of Care anchor type 2 diabetes monitoring. The four-stage monitoring cadence (baseline, week 4-8, month 3, month 6 plus annual) applies across the class with class-specific markers at each stage per FDA prescribing information. The PSI physician directory provides verified physicians ordering comprehensive GLP-1 baseline bloodwork across primary care, endocrinology, weight medicine, and other relevant specialties.
How to Approach Your Decision
- For Wegovy or Saxenda chronic weight management, expect A1c, eGFR, lipase, lipid panel plus TSH and pregnancy testing.
- For Ozempic, Victoza, or Trulicity type 2 diabetes, expect A1c, eGFR, lipase, lipid panel per ADA 2024 Standards of Care.
- For Zepbound or Mounjaro tirzepatide therapy, expect the same four foundational markers plus class-specific additions.
- For patients with cardiovascular disease, expect cardiovascular risk stratification supporting SELECT 2023 framework.
- For pregnant or potentially pregnant patients, expect pregnancy testing baseline plus contraception counseling.
- For patients with personal or family history of MTC, GLP-1 receptor agonist therapy is contraindicated per boxed warnings.
- For compounded GLP-1 preparations, expect AMA Code 1.1.5 documentation plus 503A or 503B pharmacy verification.
- For telehealth GLP-1 therapy, expect bloodwork orders through Quest Diagnostics, LabCorp, or local laboratory networks.
Limitations and Caveats
- The four foundational baseline markers apply across the GLP-1 receptor agonist class. A1c, eGFR via creatinine, lipase, and lipid panel are required for Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, and Victoza.
- Class-specific markers apply contextually per FDA labels. TSH baseline applies for medullary thyroid carcinoma boxed warning screening. Pregnancy testing applies for patients of reproductive age.
- Cardiovascular outcomes monitoring is anchored in SELECT 2023, SUSTAIN-6, LEADER, and SURMOUNT-1. Baseline lipid panel supports the cardiovascular risk stratification framework.
- The FDA acute pancreatitis warning applies across GLP-1 receptor agonist labels. Baseline lipase establishes pre-existing pancreatic marker status before therapy initiation.
- Monitoring follows a four-stage cadence across the therapy course. Baseline week 0, early follow-up week 4 to 8, stabilization month 3, maintenance month 6 plus annual.
- Compounded GLP-1 preparations operate under AMA Code 1.1.5 framework. Verify physician pharmacy verification including 503A state license or 503B FDA registration and PCAB plus USP compliance.
- For pregnant or potentially pregnant patients, GLP-1 receptor agonist therapy is contraindicated per FDA labels. Pregnancy testing and contraception counseling apply.
- The ADA 2024 Standards of Care anchor type 2 diabetes monitoring across the class. Glycemic targets, monitoring intervals, and dose titration follow ADA guidance.
What's Marketed vs What's Studied
7 common claims, corrected.
“A simple weight management appointment does not require comprehensive bloodwork.”
GLP-1 receptor agonist therapy for chronic weight management requires baseline hemoglobin A1c, eGFR via creatinine, lipase, lipid panel, TSH given the medullary thyroid carcinoma boxed warning, and pregnancy testing for patients of reproductive age. The FDA labels specify the framework.
“Compounded semaglutide bloodwork is the same as FDA-approved Wegovy or Ozempic.”
Compounded semaglutide preparations operate outside FDA pre-market approval. The compounded preparation requires AMA Code of Medical Ethics 1.1.5 documentation plus physician verification of 503A state pharmacy or 503B FDA-registered outsourcing facility. Baseline bloodwork rigor is comparable but the documentation framework differs.
“Type 2 diabetes management with Ozempic does not require kidney function monitoring.”
FDA prescribing information for Ozempic specifies kidney function assessment before initiation and during therapy. Baseline eGFR via creatinine supports dose adjustment for patients with chronic kidney disease. For patients on dialysis or end-stage renal disease, the FDA label includes specific contraindications and dose modifications.
“Lipase elevation during GLP-1 therapy always means pancreatitis.”
Lipase elevation during GLP-1 receptor agonist therapy requires clinical context evaluation. Symptomatic elevation with persistent severe abdominal pain or vomiting triggers FDA prescribing information discontinuation pending pancreatic evaluation. Asymptomatic elevation may not warrant discontinuation. Your physician determines clinical significance.
“TSH baseline is not required because GLP-1 drugs do not affect the thyroid.”
Some GLP-1 receptor agonist FDA labels include a medullary thyroid carcinoma boxed warning based on rodent thyroid C-cell tumor findings. Baseline TSH supports the boxed warning contraindication screening including personal or family history of MTC or multiple endocrine neoplasia syndrome type 2.
“Cardiovascular outcomes trials only apply to type 2 diabetes patients.”
SELECT 2023 (Lincoff et al. NEJM) demonstrated cardiovascular benefit of semaglutide 2.4 mg in obesity without diabetes plus established cardiovascular disease. The 17,604-patient trial supports cardiovascular monitoring even in non-diabetic obesity. Baseline lipid panel anchors the framework across indications.
“Telehealth GLP-1 prescribing skips bloodwork because the physician cannot draw blood.”
Telehealth GLP-1 bloodwork orders go through external laboratory networks like Quest Diagnostics or LabCorp. The patient visits the laboratory for sample collection. Results are delivered electronically to the prescribing physician for clinical interpretation. The framework follows FDA prescribing information for the specific drug and indication.
Common Questions
What baseline bloodwork is required before Wegovy?
Baseline panel for Wegovy (semaglutide 2.4 mg for chronic weight management, NDA 215256) includes hemoglobin A1c for unrecognized diabetes screening, eGFR via creatinine, lipase, lipid panel, TSH for medullary thyroid carcinoma boxed warning screening, and pregnancy testing for patients of reproductive age. The FDA label anchors the framework.
What baseline bloodwork is required before Ozempic?
Baseline panel for Ozempic (semaglutide for type 2 diabetes, NDA 209637) includes hemoglobin A1c for glycemic control baseline, eGFR via creatinine, lipase, and lipid panel per FDA prescribing information and ADA 2024 Standards of Care. TSH applies for medullary thyroid carcinoma boxed warning screening.
What baseline bloodwork is required before Zepbound or Mounjaro?
Baseline panel for tirzepatide (Zepbound NDA 217806 for weight management, Mounjaro NDA 215866 for type 2 diabetes) includes the same four foundational markers: A1c, eGFR, lipase, lipid panel. The medullary thyroid carcinoma boxed warning applies with baseline TSH supporting contraindication screening.
What baseline bloodwork is required before Saxenda or Victoza?
Baseline panel for liraglutide (Saxenda for weight management, Victoza for type 2 diabetes) includes the same four foundational markers: A1c, eGFR, lipase, lipid panel. Additional baseline markers per FDA labels include TSH for the boxed warning context and pregnancy testing for reproductive age patients.
How often is bloodwork repeated during GLP-1 therapy?
Bloodwork follows a four-stage cadence: baseline at week 0, early follow-up at week 4 to 8, stabilization at month 3, and maintenance at month 6 with annual continuation. The specific markers tested at each stage follow FDA prescribing information and ADA 2024 Standards of Care for type 2 diabetes contexts.
Why is lipase required at baseline?
FDA prescribing information for all GLP-1 receptor agonists includes an acute pancreatitis warning based on post-marketing reports. Baseline lipase establishes pre-existing pancreatic marker status. For patients with elevated baseline lipase, additional evaluation for pancreatic disease is required before therapy initiation.
Why is TSH baseline required for some GLP-1 drugs?
Some FDA labels include a medullary thyroid carcinoma boxed warning based on rodent thyroid C-cell tumor findings. Baseline TSH supports the boxed warning contraindication screening including patients with personal or family history of MTC or multiple endocrine neoplasia syndrome type 2.
Why is pregnancy testing required at baseline?
GLP-1 receptor agonist therapy is contraindicated in pregnancy per FDA prescribing information. Baseline pregnancy testing applies for patients of reproductive age. Contraception counseling is standard during therapy. Discontinuation applies if pregnancy is planned or detected during therapy.
How is cardiovascular monitoring done during GLP-1 therapy?
Cardiovascular monitoring includes baseline lipid panel and blood pressure assessment plus cardiovascular history review. The framework anchors in SELECT 2023 (semaglutide MACE reduction in obesity), SUSTAIN-6 (semaglutide cardiovascular benefit in T2D), LEADER (liraglutide cardiovascular benefit), and SURMOUNT-1 (tirzepatide weight reduction).
Can my primary care physician order GLP-1 baseline bloodwork?
Yes. Primary care can order baseline bloodwork for GLP-1 receptor agonist therapy including chronic weight management and type 2 diabetes indications. For complex cardiovascular contexts, specialty coordination with cardiology applies. For complex type 2 diabetes contexts, specialty coordination with endocrinology applies per ADA 2024 Standards of Care.
Will my insurance cover GLP-1 baseline bloodwork?
Insurance coverage for GLP-1 baseline bloodwork generally has prior authorization frameworks supporting the testing when the indication is FDA-approved. For chronic weight management, coverage depends on BMI threshold and weight-related comorbidities. For type 2 diabetes, coverage is standard. Verify coverage with your insurance plan.
What if my baseline bloodwork shows pre-existing lipase elevation?
Pre-existing lipase elevation requires additional pancreatic evaluation before GLP-1 receptor agonist therapy initiation. The evaluation may include imaging (abdominal ultrasound or CT), additional pancreatic markers (amylase), and gastroenterology specialty consultation. Your physician will determine the framework based on the clinical context.
What if I have a personal or family history of medullary thyroid carcinoma?
GLP-1 receptor agonist therapy is contraindicated per FDA boxed warnings for patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Alternative therapy applies per ADA 2024 Standards of Care for type 2 diabetes or per FDA labels for chronic weight management.
Do compounded GLP-1 prescriptions require the same bloodwork?
Yes. Compounded semaglutide or tirzepatide preparations require comparable baseline bloodwork per AMA Code of Medical Ethics 1.1.5 framework. The documentation framework includes risk-benefit assessment, alternatives considered (including FDA-approved Wegovy or Zepbound), and patient understanding. Physician pharmacy verification of 503A or 503B applies.
How is GLP-1 therapy monitored in patients with chronic kidney disease?
Baseline eGFR via creatinine supports kidney function assessment. FDA prescribing information specifies dose adjustment for moderate kidney impairment and may specify contraindication for severe impairment or end-stage renal disease. Monitoring intervals follow FDA labels with specialty coordination through nephrology for established kidney disease.
Can I get GLP-1 baseline bloodwork through telehealth?
Yes. Telehealth GLP-1 bloodwork orders go through external laboratory networks like Quest Diagnostics, LabCorp, or local laboratory networks. The patient visits the laboratory for sample collection. Results are delivered electronically to the prescribing physician for clinical interpretation per FDA prescribing information.
What happens if I miss a monitoring interval during GLP-1 therapy?
Missing a monitoring interval triggers a clinical conversation with your prescribing physician. The physician will evaluate whether dose continuation is appropriate pending re-testing or whether therapy pause applies pending the next clinic visit. The framework operates under FDA prescribing information and ADA 2024 Standards of Care for type 2 diabetes.
Where can I find a physician for GLP-1 therapy?
The PSI physician directory provides verified physicians across major US cities including peptide therapy experience verification, state medical board license verification, ABMS board certification, and AMA Code 1.1.5 documentation practice verification. The directory covers primary care, endocrinology, and weight medicine specialists per indication.
Evidence Ranking
Rank 1
Hemoglobin A1c
Strongest evidence anchoring: ADA 2024 Standards of Care diagnostic thresholds plus FDA prescribing information across all GLP-1 RA drugs for type 2 diabetes monitoring and chronic weight management screening.
Rank 2
eGFR via creatinine
Strong evidence anchoring: FDA prescribing information specifies kidney function assessment and dose adjustment across GLP-1 RA class for Wegovy, Ozempic, Zepbound, and Mounjaro.
Rank 3
Lipid panel
Strong evidence anchoring: SELECT 2023 (semaglutide ~20 percent MACE reduction in obesity), SUSTAIN-6 (T2D cardiovascular benefit), and LEADER (liraglutide T2D cardiovascular benefit) anchor framework.
Rank 4
Lipase
Strong evidence anchoring: FDA acute pancreatitis warning common across GLP-1 RA labels. Baseline lipase establishes pre-existing elevation status before therapy initiation.
Rank 5
TSH (boxed warning context)
Moderate evidence anchoring: medullary thyroid carcinoma boxed warning in some GLP-1 labels (rodent thyroid C-cell tumor findings). FDA-label-specific application.
Rank 6
Pregnancy testing
Strong contextual anchoring: GLP-1 receptor agonist therapy is contraindicated in pregnancy per FDA labels. Applies for patients of reproductive age with contraception counseling.
Sourcing Checklist
Order baseline bloodwork through prescribing physician with documented clinical interpretation.
Self-ordered direct-to-consumer bloodwork is not a substitute for physician-ordered baseline. AMA Code 1.1.5 informed consent for off-label or compounded prescribing requires physician clinical interpretation.
Match the baseline panel to the specific GLP-1 drug and indication per FDA prescribing information.
Wegovy and Saxenda apply chronic weight management framework. Ozempic, Victoza, and Mounjaro apply ADA 2024 Standards of Care for type 2 diabetes.
Verify medullary thyroid carcinoma history before therapy initiation.
GLP-1 receptor agonist therapy is contraindicated per FDA boxed warnings for patients with personal or family history of MTC or multiple endocrine neoplasia syndrome type 2.
Verify pregnancy status and discuss contraception during therapy.
GLP-1 receptor agonist therapy is contraindicated in pregnancy per FDA labels. Baseline pregnancy testing applies for reproductive age patients. Contraception counseling is standard.
For compounded GLP-1 preparations, expect AMA Code 1.1.5 informed consent documentation.
The documentation includes risk-benefit assessment, FDA-approved alternatives considered (Wegovy or Zepbound), monitoring requirements, and patient understanding.
Verify physician pharmacy verification for compounded GLP-1 pathways.
Verification includes 503A state pharmacy board license or 503B FDA registration, PCAB accreditation, USP Chapter 797 and 800 compliance, and third-party testing practices.
Expect four-stage monitoring cadence across the therapy course.
Baseline week 0, early follow-up week 4 to 8, stabilization month 3, maintenance month 6 with annual continuation. Class-specific markers apply at each stage.
For patients with cardiovascular disease, expect cardiovascular risk stratification at baseline.
The framework anchors in SELECT 2023, SUSTAIN-6, LEADER, and SURMOUNT-1 cardiovascular outcomes trials. Baseline lipid panel and blood pressure assessment apply.
For telehealth GLP-1 consultation, expect bloodwork orders through external laboratory networks.
Quest Diagnostics, LabCorp, and local laboratory networks support telehealth bloodwork ordering with electronic results delivery to the prescribing physician.
Regulatory Context
The regulatory framework governing GLP-1 receptor agonist therapy evolves continuously. FDA prescribing information for each FDA-approved GLP-1 receptor agonist updates with each labeling cycle including new indications, contraindications, monitoring specifications, and adverse event profile updates. ADA Standards of Care updates annually for type 2 diabetes monitoring. The FDA Compounding Quality Act enforcement landscape evolves with state pharmacy board oversight cycles and 503B outsourcing facility inspection cadences specifically for compounded semaglutide and tirzepatide. AMA Code of Medical Ethics 1.1.5 and 2.1.1 frameworks remain foundational with periodic refinements. PSI tracks regulatory changes and updates this page per the Editorial Standards review cadence.
Comparison
| Drug (FDA NDA) | Indication | Core Baseline Markers | Cardiovascular Anchor |
|---|---|---|---|
| Wegovy (NDA 215256) | Chronic weight management | A1c, eGFR, lipase, lipid, TSH, preg test | SELECT 2023 (Lincoff et al. NEJM) |
| Ozempic (NDA 209637) | Type 2 diabetes | A1c, eGFR, lipase, lipid, TSH | SUSTAIN-6 (Marso et al. NEJM 2016) |
| Zepbound (NDA 217806) | Chronic weight management | A1c, eGFR, lipase, lipid, TSH, preg test | SURMOUNT-1 (Jastreboff et al. NEJM 2022) |
| Mounjaro (NDA 215866) | Type 2 diabetes | A1c, eGFR, lipase, lipid, TSH | SURPASS trials (head-to-head vs semaglutide) |
| Saxenda (liraglutide 3.0 mg) | Chronic weight management | A1c, eGFR, lipase, lipid, TSH, preg test | SCALE trials weight management |
| Victoza (liraglutide) | Type 2 diabetes | A1c, eGFR, lipase, lipid, TSH | LEADER (Marso et al. NEJM 2016) |
| Compounded semaglutide | Off-label or compounded indication | Same as Wegovy or Ozempic plus AMA 1.1.5 documentation | Class-level cardiovascular evidence applies |
| Compounded tirzepatide | Off-label or compounded indication | Same as Zepbound or Mounjaro plus AMA 1.1.5 documentation | Class-level cardiovascular evidence applies |
Who This Applies To
- · Adult preparing for Wegovy chronic weight management with BMI 30 or higher plus baseline bloodwork.
- · Adult preparing for Ozempic type 2 diabetes therapy per ADA 2024 Standards of Care.
- · Adult preparing for Zepbound or Mounjaro tirzepatide therapy per FDA labels and SURMOUNT-1.
- · Adult preparing for Saxenda or Victoza liraglutide therapy per FDA labels and LEADER.
- · Adult with established cardiovascular disease preparing for GLP-1 RA therapy under SELECT framework.
- · Adult of reproductive age requiring pregnancy testing and contraception counseling per FDA labels.
- · Adult with personal or family history of MTC requiring contraindication evaluation per boxed warnings.
- · Adult considering compounded semaglutide or tirzepatide under AMA Code 1.1.5 framework.
- · Adult planning four-stage monitoring cadence across the GLP-1 RA therapy course.
- · Adult with chronic kidney disease requiring dose adjustment per FDA labels and specialty coordination.
Verdict
GLP-1 receptor agonist therapy requires baseline hemoglobin A1c, eGFR, lipase, and lipid panel per FDA labels. The framework anchors in ADA 2024 Standards of Care for type 2 diabetes monitoring. Additional context-specific markers include TSH given the medullary thyroid carcinoma boxed warning. Pregnancy testing applies for patients of reproductive age. SELECT 2023 supports cardiovascular outcomes monitoring with semaglutide. SUSTAIN-6 supports cardiovascular benefit in type 2 diabetes. SURMOUNT-1 supports tirzepatide weight reduction efficacy. Monitoring follows a four-stage cadence across the therapy course. Patients should consult primary care or specialty practice.
In Plain Terms
Drugs in the GLP-1 family include Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, and Victoza. Before starting any of these drugs, you need four basic blood tests. The tests are A1c (blood sugar), kidney function, lipase (pancreas), and a lipid panel. The FDA labels for these drugs also recommend thyroid testing in some cases. Pregnancy testing is also done if applicable. Bloodwork is repeated at baseline, week 4-8, month 3, and month 6 then yearly. Bring any prior labs to your appointment.
GLP-1 drugs like Wegovy, Ozempic, Zepbound, and Mounjaro need four basic blood tests before you start. Your doctor checks your blood sugar (A1c), kidney function, pancreas markers (lipase), and cholesterol. Some labels also need thyroid testing and pregnancy testing. Tests are repeated at baseline, week 4-8, month 3, and month 6 then yearly. Bring any prior labs to your appointment.
For GLP-1 receptor agonist therapy, physician selection through state medical board license verification, ABMS board certification, peptide experience verification, and AMA Code 1.1.5 framework adherence is the legal and clinical gate. PSI maintains a vetted directory of practitioners ordering comprehensive GLP-1 baseline bloodwork per FDA prescribing information across primary care, endocrinology, weight medicine, and other relevant specialties.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Related Conditions
Related Education
Featured Compounds
Common Contexts
- · Adult preparing for Wegovy chronic weight management therapy with baseline panel ordering
- · Adult preparing for Ozempic type 2 diabetes therapy per ADA 2024 Standards of Care
- · Adult preparing for Zepbound or Mounjaro tirzepatide therapy per FDA labels
- · Adult preparing for Saxenda or Victoza liraglutide therapy per FDA labels
- · Adult comparing FDA-approved GLP-1 therapy versus compounded GLP-1 preparation pathways
- · Adult with established cardiovascular disease preparing for SELECT framework anchoring
- · Adult with type 2 diabetes preparing for SUSTAIN-6 cardiovascular benefit framework
- · Adult of reproductive age preparing for pregnancy testing and contraception counseling
- · Adult considering telehealth GLP-1 therapy with external laboratory bloodwork ordering
- · Adult planning four-stage monitoring cadence across the GLP-1 therapy course
Important Context
This page is educational and does not constitute medical advice. The information presented reflects FDA prescribing information for GLP-1 receptor agonists including Wegovy NDA 215256, Ozempic NDA 209637, Zepbound NDA 217806, Mounjaro NDA 215866, Saxenda, and Victoza, ADA 2024 Standards of Care, SELECT 2023 cardiovascular outcomes trial, SUSTAIN-6, LEADER, SURMOUNT-1, AMA Code of Medical Ethics 1.1.5 and 2.1.1 for off-label and compounded prescribing, the FDA Compounding Quality Act of 2013, and FDA MedWatch adverse event reporting framework as referenced.
Your physician will order the specific baseline panel appropriate to the specific GLP-1 receptor agonist, your indication (type 2 diabetes versus chronic weight management), your clinical context including cardiovascular history and reproductive status, and your prior bloodwork records. The framework described here is general and does not substitute for individualized clinical judgment. Specialty coordination strengthens complex decisions across primary care, endocrinology, weight medicine, cardiology, and other relevant specialties.
Self-ordering of bloodwork through direct-to-consumer laboratory services is not a substitute for physician-ordered baseline assessment with documented clinical interpretation. Quality clinical practice orders bloodwork in the context of the indication-specific evaluation and reviews results with the patient.
Educational content only. Discuss with your physician before pursuing GLP-1 receptor agonist therapy. For compounded semaglutide or tirzepatide pathways, verify pharmacy quality assurance per the FDA Compounding Quality Act of 2013 including 503A state license, 503B FDA registration, PCAB accreditation, USP Chapter 797 and 800 compliance, and third-party testing practices.
Sources and Citations
- [1] FDA Prescribing Information: Wegovy (semaglutide) injection 2.4 mg for chronic weight management · 2024 · FDA NDA 215256 · Source
- [2] FDA Prescribing Information: Ozempic (semaglutide) injection for type 2 diabetes · 2024 · FDA NDA 209637 · Source
- [3] FDA Prescribing Information: Zepbound (tirzepatide) injection for chronic weight management · 2024 · FDA NDA 217806 · Source
- [4] FDA Prescribing Information: Mounjaro (tirzepatide) injection for type 2 diabetes · 2024 · FDA NDA 215866 · Source
- [5] FDA Prescribing Information: Saxenda (liraglutide) injection 3.0 mg for chronic weight management · 2023 · FDA NDA 206321 · Source
- [6] FDA Prescribing Information: Victoza (liraglutide) injection for type 2 diabetes · 2023 · FDA NDA 022341 · Source
- [7] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial, 17,604 patients) · New England Journal of Medicine · 2023 · DOI
- [8] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, 2,539 patients) · New England Journal of Medicine · 2022 · DOI
- [9] Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6, 3,297 patients) · New England Journal of Medicine · 2016 · DOI
- [10] Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER, 9,340 patients) · New England Journal of Medicine · 2016 · DOI
- [11] Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) · New England Journal of Medicine · 2021 · DOI
- [12] American Diabetes Association. Standards of Care in Diabetes 2024 · Diabetes Care · 2024 · DOI
- [13] AACE Comprehensive Clinical Practice Guideline for Medical Care of Patients with Obesity 2022 Update · Endocrine Practice · 2022
- [14] AMA Code of Medical Ethics Opinion 1.1.5: Off-label and Investigational Use of Pharmaceuticals · American Medical Association · 2024 · Source
- [15] AMA Code of Medical Ethics Opinion 2.1.1: Informed Consent · American Medical Association · 2024 · Source
- [16] FDA Compounding Quality Act of 2013: 503A pharmacy and 503B outsourcing facility framework · US Food and Drug Administration · 2013 · Source
- [17] FDA Alert: Concerns Regarding the Use of Compounded GLP-1 Drugs · US Food and Drug Administration · 2024 · Source
- [18] FDA MedWatch: The FDA Safety Information and Adverse Event Reporting Program · US Food and Drug Administration · 2024 · Source
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.